
March 13 (Reuters) - Amgen Inc AMGN.O:
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
AMGEN INC: NO NEW SAFETY SIGNALS WERE IDENTIFIED FROM STUDY
AMGEN: UPLIZNA REGULATORY FILING ACTIVITIES UNDERWAY, SUBMISSION TO BE COMPLETE IN H1 2025